Ones To Watch News
Refine Search
Biotechnology
Shares of Sweden’s immune-oncology firm Alligator Bioscience were up almost 160% at 0.11 kronor by early afternoon today, after the company reported updated results from the Phase II OPTIMIZE-1 study evaluating mitazalimab. 26 February 2025
Biotechnology
Candel Therapeutics has released final data from a Phase II trial of its investigational immunotherapy, CAN-2409, in non-metastatic pancreatic ductal adenocarcinoma (PDAC), showing a notable survival benefit. 26 February 2025
Biotechnology
Swiss biotech company Idorsia has revised its collaboration terms with Viatris, reducing its financial commitment to the development of two late-stage drugs. In exchange, the company has accepted a significant reduction in future potential earnings. 26 February 2025
Pharmaceutical
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a novel dopamine-1 receptor antagonist, in subjects with Tourette syndrome. 26 February 2025
Pharmaceutical
Cardiovascular diseases specialist Kiniksa Pharmaceuticals International has announced updates to its pipeline alongside fourth quarter and full year 2024 financial results. 26 February 2025
Pharmaceutical
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda (TYO: 4502). The new deal expands on their initial 2021 partnership, valued at around $500 million, centered on chemoproteomics-based approaches to address "undruggable" targets. 26 February 2025
Pharmaceutical
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s Medincell announced that the supplemental New Drug Application (sNDA) for Uzedy (risperidone) extended-release injectable suspension for the maintenance treatment of bipolar-I (BP-I) in adults has been accepted for filing by the US Food and Drug Administration (FDA). 26 February 2025
Biotechnology
US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel treatment approaches in inflammatory bowel disease (IBD). 25 February 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. 25 February 2025
Biotechnology
Boston, USA-based biotech Nimbus Therapeutics today revealed that, along with partner Eli Lilly, it has achieved a significant pre-clinical milestone in their research collaboration targeting AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases. 25 February 2025
Biotechnology
UK-based Swarm Oncology, a biotech developing T-cell therapies to achieve long-term remission in advanced solid cancers, has announced a strategic partnership with cell and gene therapy-focused contract development and manufacturing organization Cellex Cell Professionals. 25 February 2025
Biotechnology
Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial collaboration with Pfizer to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of the US pharma giant’s antibody drug conjugates (ADCs) across multiple solid tumor settings. 25 February 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved label changes for Sublocade (buprenorphine extended-release), including a rapid initiation protocol and alternative injection sites. 25 February 2025
Pharmaceutical
US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint. 24 February 2025
Pharmaceutical
The US Food and Drug Administration (FDA) late Friday revealed it has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. 24 February 2025
Biotechnology
Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks. 21 February 2025
Biotechnology
French biotech tart-up EG 427 has successfully closed a 27 million-euro ($28.4 million) Series B financing round co-led by Andera Partners and Bpifrance - as part of the InnoBio investment strategy. 21 February 2025
Biotechnology
Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers Squibb to out-license to the US pharma major its pyroglutamate-amyloid-beta (PyroGlu-Aβ) antibody program. Closing of the agreement has been completed and BioArctic will receive an upfront payment of $100 million. 20 February 2025
Pharmaceutical
US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with treatment-resistant depression (TRD) did not demonstrate a statistically significant improvement on the primary endpoint. 20 February 2025
Biotechnology
Eleva, a German company developing difficult-to-produce biologics based on a breakthrough moss-based platform, has announced the appointment of Martin Bauer as its chief medical officer (CMO). 20 February 2025
Biotechnology
Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration with Genentech, a subsidiary of Roche , to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology. 22 May 2025
Pharmaceutical
Swiss reproductive and women’s health medicines specialist ReproNovo today announced the successful closing of a $65 million Series A financing round, which will be used to advance its pipeline of multiple Phase II programs. 21 May 2025
Pharmaceutical
North Carolina, USA-based vTv Therapeutics has announced that screening has been reinitiated in the company’s CATT1 Phase III trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). 21 May 2025
Biotechnology
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
Biotechnology
UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. 21 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Pharmaceutical
Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults living with mild, moderate and severe OSA, and across all weight classes. 20 May 2025
Biotechnology
German vaccine pioneer BioNTech today revealed that its UK subsidiary has signed a grant agreement with the UK government to broaden the company’s R&D activities for innovative medicines in the UK. 20 May 2025
Biotechnology
Swiss gene-editing specialist CRISPR Therapeutics and San Diego, USA-based Sirius Therapeutics, which is developing innovative small interfering RNA (siRNA) therapies, announced a strategic partnership to develop and commercialize siRNA therapies. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biotechnology
Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round. 19 May 2025
Biotechnology
US human genetics biotech 23andMe today revealed it has entered into a definitive agreement for the sale of the company to Regeneron Pharmaceutical, whose shares climbed 2% following the announcement 19 May 2025
Pharmaceutical
USA-based rare disease company Applied Therapeutics saw its shares rise nearly 23% to $0.60 on Friday, ahead of a planned presentation on its lead candidate, govorestat, at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20 in Edinburgh, Scotland. 19 May 2025
Biotechnology
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Biotechnology
Telomir Pharmaceuticals, a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. 16 May 2025
Pharmaceutical
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Biotechnology
US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million. 16 May 2025
Biotechnology
New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. 16 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze